Construction cyclicality — a US/European building downturn hits volumes, pricing and the roll-up engine at once
One-line thesis. CRH is the leading North American building-materials platform (aggregates, cement, asphalt, paving, precast), quietly re-rated by its US listing and infrastructure-spend tailwind: FY25 revenue $37.4B (+9%), Adjusted-EBITDA margin expanding, 23% ROE and a cheap ~8× EV/EBITDA — a genuinely good business at a fair price, but a cyclical one with mid-single-digit organic growth, so we own it tactically, not as a core compounder.
◆ Synthos call — WatchCRH is a business we want at a price we don't have — it becomes a Buy below ~$115; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Sturdy 1.5× net-debt/EBITDA & cheap 8× EV/EBITDA, but cyclical, ~1.19 beta, −18% off highs.
Mid-single-digit organic growth, roll-up driven; a $72B cyclical is no multibagger.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 23%/yrTo justify today’s $108, earnings would have to compound roughly 23% a year for 10 years (9% discount rate). Analysts forecast ~11%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
CRH makes the boring but essential stuff that roads and buildings are made of: crushed stone (aggregates), cement, asphalt, ready-mixed concrete, and pre-made concrete products like pipes and drainage. It is the biggest player of its kind in North America, and it earns money every time a highway gets repaved or a data center gets built — and US infrastructure spending is high right now.
Is the stock cheap or expensive? Cheap-ish. You pay about 8 dollars of company value for every 1 dollar of yearly cash earnings (EV/EBITDA ~8×) — a bargain multiple compared with most of the market. The catch is that CRH is a cyclical business: when construction slows down (recession, high interest rates), its sales and profits fall. So the low price is partly the market pricing in that risk. Our verdict is Buy — Tactical: a reasonable value with a decent dividend, worth owning as a smaller "satellite" position, not a bet-the-farm holding.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (moderate, leans safe). The balance sheet is sturdy and the valuation is cheap, which cushions the downside — but it's cyclical and the stock has already dropped ~18% from its high, so it can swing.
Growth Quality 6/10 (solid). A well-run, profitable business growing steadily in the mid-to-high single digits — good, but not a fast grower.
Exponential Potential 3/10 (low). This is a $72 billion industrial giant that grows by buying up smaller rivals and riding building cycles. Don't expect it to double quickly.
The one big worry: construction is cyclical. A downturn in US or European building would hit CRH's volumes, its pricing power, and its acquisition machine all at the same time.
A note on honesty: unlike some names we cover, no outside expert in our knowledge base has written about CRH. This verdict rests purely on the numbers and the industry setup — not on any analyst's conviction. We say so plainly.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = CRH · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$107.53
Market cap$72B
P/E trailing5×
P/E FY26E / FY27E18× / 16×
EV / Sales1.6×
EV / EBITDA8.1×
Gross margin35.6%
Net margin9.0%
Dividend yield1.41%
Beta1.187
52-wk range$93 – $131
RSI(14)55
50 / 200-DMA$109 / $115
12-mo return+15% (SPY +21%)
Street target$141 ($120–$166)
Analyst grades14 Buy · 6 Hold · 0 Sell
FMP ratingA-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on CRH · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
CRH plc (NYSE: CRH) is a Dublin-headquartered, US-listed global building-materials company founded in 1936, with ~81,900 employees. After moving its primary listing to the NYSE in 2023, it is now an S&P 500 constituent and the largest building-materials business in North America. It operates through three segments:
Americas Materials Solutions — aggregates, cement, asphalt, ready-mixed concrete, and paving/construction services (the core, most cyclical-but-highest-return heavy-materials engine).
Americas Building Solutions — manufactured building products: precast/pre-stressed concrete (vaults, pipes, manholes), drainage, utility/water infrastructure products, outdoor-living/hardscape.
International Solutions — materials and building products across Europe and rest-of-world.
Fiscal year ends December 31. The business model is a materials + solutions platform: own the aggregates/cement reserves (a local-monopoly, high-barrier asset), then bolt on downstream products and services, and compound via a disciplined acquisition roll-up funded by strong free cash flow.
Revenue mix (FY2025, from FMP segmentation, reported in EUR):
By type: Product €28.75B · Service €8.69B — i.e. roughly three-quarters product, one-quarter service/paving.
By geography: The US is the dominant market (FY24 detail: United States €21.8B of ~€33B ≈ ~66% US, Rest of Europe €7.0B, United Kingdom €4.0B). FY25 partial disclosure shows Rest of Europe €7.4B and Rest of World €3.5B. The revenue base is US-centric, which is the whole re-rating thesis: US infrastructure (IIJA), reshoring/data-center construction, and better pricing than Europe.
(Note: FMP reports segmentation in EUR while the income statement is in USD — treat the segment split as a mix guide, not a dollar reconciliation.)
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of CRH in the Synthos knowledge base. total_claims = 0, net-bullish voices = 0.
This is stated plainly and honestly: no distilled expert (podcast/investor-panel) voice in our KB has made a traceable claim about CRH. There are therefore no claim_id values to cite, and we fabricate none. The Synthos house standard is that conviction must reconcile to a real claim — so this note carries no conviction-track signal.
The verdict below is entirely fundamentals- and quant-driven: reported financials, live FMP analyst consensus (labeled as estimates), balance-sheet and valuation math, management's own SEC-filed guidance (half-weighted), and the sell-side grade distribution (context only). Where the Street is cited it is context, not our anchor. Read this as a quantitative value screen with a full financial workup — not as a high-breadth conviction call like our flagship names.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Moderate (leans safe)
Net-debt/EBITDA 1.5× and a cheap 8.1× EV/EBITDA cushion the downside; offsetting: ~1.19 beta, construction cyclicality, and the stock already −18% off its high and below both moving averages.
Growth Quality
6 · Solid
~13% forward EPS CAGR and ~6% revenue CAGR (FY25→FY30E), Adjusted-EBITDA margin expanding, 23.5% ROE / 11.4% ROIC — a well-run compounder, but growth is mid-single-digit organic + M&A, not elite.
Exponential Potential
3 · Low
Mid-single-digit organic top-line, roll-up-driven, in a mature cyclical industry; a $72B cap in construction materials is a compounder, not a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Infrastructure/reshoring demand stays strong, pricing holds, roll-up keeps compounding; FY27E EPS beats to ~$7.2 (vs $6.71 cons) and the multiple re-rates toward the quality of the aggregates peers at ~22×.
~$158 (+47%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $6.71; a durable mid-teens-return cyclical compounder earns a ~19× forward multiple.
~$128 (+19%)
Bear
US/EU construction downturn: volumes and pricing soften, M&A slows; FY27E EPS misses to ~$5.5 and the multiple de-rates to a trough-cyclical ~16×.
~$88 (−18%)
Synthos fair value = the base case, ~$128 (+19%), with the full $88–$158 span as the honest range. This anchor sits below the Street's $141 consensus (we discount the cyclical multiple more than the sell-side does) and our bear ($88) sits near the 52-week low, taking a construction downturn seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CRH is a quality cyclical compounder with low exponential potential:
Forward growth: revenue CAGR FY25→FY30E ~6.5% ($37.4B → $51.4B); EPS CAGR ~12.8% ($5.51 → $10.04) as EBITDA margin expands and buybacks shrink the share count.
Acceleration (the 2nd derivative) is roughly flat-to-modest: revenue growth ~+9% (FY25) → +6% (FY26E) → +5.5% (FY27E). This is a mature, steady grower — not an accelerating inflection. Growth is powered as much by acquisitions and pricing as by organic volume. Per our flagship philosophy we hunt forward next-exponentials over trailing compounders — CRH is firmly a compounder, and a cyclical one at that.
Room to run: the North American building-materials TAM is large and infrastructure spend is a real multi-year tailwind, but at $72B market cap in a mature, consolidating industry the law of large numbers applies: a 3× from here implies a ~$215B building-materials company, larger than anything in the sector. CRH compounds mid-teens; it does not multibag.
Reinvestment runway: genuine and disciplined — ~$2.7B/yr capex plus ~$3.7B/yr of value-accretive acquisitions, funded by ~$2.9B FCF and debt capacity. The roll-up engine is the real growth story, and it's intact.
Exponential Potential: Low (3/10). Own CRH for a cheap multiple + ~13% EPS compounding + a growing dividend + buybacks — not for a fast multibagger. That honest framing is why it belongs in a tactical/value sleeve, not a growth-exponential sleeve.
Revenue: FY25 $37.45B, +9.0% (FY24 $34.35B, +8.2% on FY23 $31.76B). Steady mid-to-high-single-digit growth, part organic/pricing, part M&A.
Seasonality (important): CRH is highly seasonal — Q1 is structurally a loss quarter (construction slows in winter). Q1'26 posted revenue $7.37B but a net loss of −$180M (−$0.27 EPS), driven by depreciation, an impairment tied to a divestiture, and higher interest — this is normal seasonality, not deterioration. Q3 is the profit peak (Q3'25 EPS $2.23).
Margins: gross 35.6% TTM, EBITDA ~19.4% TTM (FY25 EBITDA $7.48B), net ~7–9%. Adjusted-EBITDA margin has been expanding (management cites +70bps in Q1'26). Aggregates-led mix supports pricing power.
Earnings: net income $3.73B FY25 (diluted EPS $5.51), up from $3.46B / $5.02 in FY24. Returns are strong for the sector: ROE 23.5%, ROIC 11.4%, ROCE 15.4%.
Cash flow: operating CF $5.63B FY25, capex −$2.71B, FCF $2.91B; the rest of investing is ~$3.7B of acquisitions (the roll-up). FCF comfortably funds the dividend ($1.0B) and buybacks ($1.18B).
Balance sheet: net debt $15.6B, net-debt/EBITDA ~1.5× — up from ~1.0× in FY23 as M&A and buybacks ran ahead of FCF, but still solidly investment-grade (management targets a strong IG rating). Interest coverage ~6.7×. Goodwill+intangibles $15.1B (25% of assets) reflects the acquisitive model — a watch item, not a red flag.
6. Valuation — priced in or room?
CRH is cheap on cash-flow multiples and mid-range on earnings:
Forward (live consensus): P/E ~18× FY26E ($5.94) → ~16× FY27E ($6.71) → ~11× FY30E ($10.04). The multiple compresses fast if estimates hit — typical of a cyclical priced with some caution.
The read: an ~8× EV/EBITDA on a business earning 23% ROE with a real infrastructure tailwind is not demanding; the discount is the market pricing in construction cyclicality and the roll-up's goodwill. The FMP letter rating is A- (strong ROE/ROA/DCF sub-scores; weak debt-to-equity and P/B sub-scores). Street targets (context): consensus $141, high $166, low $120 — the entire sell-side range sits above today's $107.53. Our base FV $128 is more conservative than consensus because we discount the cyclical multiple; even so it implies ~+19%. Not a deep-value screaming bargain, but a reasonably-priced quality cyclical.
7. Technicals (from the FMP tech block)
Trend:corrective / below trend. $107.53 sits below the 50-DMA ($108.9) and the 200-DMA ($115.4), and the 50 is below the 200 (death-cross posture) — the opposite of a leadership uptrend.
Location:−18.2% off the 52-week high ($131.4), +15.8% off the 52-week low ($92.9). Max drawdown from peak −18.2%. The stock has been consolidating/correcting, not breaking out.
Relative strength: CRH +15.3% 12-mo vs SPY +20.6% and QQQ +30.3% — lagging both the market and the Nasdaq. Also −14.5% over 6 months vs SPY +8.4%. This is a laggard on price momentum.
Read: technicals do not confirm a fresh uptrend — CRH is below both moving averages and trailing the market. For a value/tactical entry that's not disqualifying (you're buying weakness cheaply), but there is no momentum tailwind; a reclaim of the 200-DMA (~$115) would be the technical all-clear. Patience or scaling-in is warranted.
8. Moat & competitive position
CRH's moat is local-asset scarcity + vertical integration + scale: aggregates reserves (crushed stone, sand, gravel) are heavy, low-value-to-weight, and uneconomic to ship far — so whoever owns the local quarry has a de-facto regional monopoly with pricing power. CRH layers cement, asphalt, ready-mix and downstream building products on top, and compounds via a disciplined M&A roll-up funded by FCF. The switching cost is geography; the barrier is permitting and reserves. Cyclicality is the flip side — demand tracks construction and public-infrastructure budgets.
Peer set (FMP-supplied; market cap): the closest pure comps are the US aggregates leaders Vulcan Materials (VMC) $39B and Martin Marietta (MLM) $36B — both trade at richer EV/EBITDA multiples than CRH, which is part of the re-rating case. Amrize (AMRZ) $30B (the spun-off Holcim North America business) and James Hardie (JHX) $15B are building-products comps. The rest of the FMP peer list — Agnico Eagle, BHP, Freeport, Newmont, Ecolab, Sherwin-Williams — are broad "Basic Materials" tag-alongs, not true operating comps. Against VMC/MLM, CRH is the larger, more diversified, and cheaper name, at the cost of more European/cyclical exposure and a heavier acquisition/goodwill profile.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — ~$2.7B/yr capex, ~$3.7B/yr value-accretive M&A, plus a growing dividend and steady buybacks. In Q1'26 alone management agreed $1.9B of divestitures across three non-core businesses (construction accessories, lawn & garden, MoistureShield decking) and invested ~$0.9B in nine acquisitions including Axius Water — active portfolio management toward higher-growth "connected" infrastructure (water, energy, transportation). This is a genuine strength: they are pruning as well as buying.
Insider activity: the sampled window (through 2026-07-01) shows routine director RSU awards, tax-withholding (F-InKind) dispositions, and one small officer sale (~1,492 shares at $104). No alarming discretionary insider selling cluster — normal comp mechanics.
Management's own guidance — SEC 8-K, half-weighted (they talk their own book): In the Q1'26 earnings release (filed 2026-04-30), management reaffirmed FY2026 guidance: Net income of $3.9bn–$4.1bn and Adjusted EBITDA of $8.1bn–$8.5bn, citing "favorable underlying demand across our key end-markets, underpinned by significant public investment in infrastructure and continued reindustrialization." They also raised the quarterly dividend +5% to $0.39 and announced a further $0.3bn buyback tranche. This is real, current, self-filed guidance — but it is management's self-interested framing, so we half-weight it. The FY26 net-income midpoint (~$4.0bn) is broadly consistent with the ~$3.98bn analyst consensus, which is reassuring.
10. Catalysts & what to watch
Next earnings: 2026-08-05 (Q2'26; Street EPS $2.03, revenue ~$10.7B). The key lines: organic volume vs pricing, Adjusted-EBITDA margin trend, and whether management holds/raises the FY26 guide.
US infrastructure & reshoring demand: IIJA disbursement pace, data-center/reindustrialization construction — the core demand tailwind.
Pricing power: aggregates/cement price realization vs input costs — the margin swing factor.
M&A + portfolio churn: completion of the agreed $1.9B divestitures and Axius Water close; discipline on acquisition multiples and goodwill.
Leverage: net-debt/EBITDA trending back toward ~1.0× vs staying near 1.5× — a tell on capital-allocation discipline.
Thesis tripwires (what would change the call): two consecutive quarters of organic volume decline; Adjusted-EBITDA margin compression; net-debt/EBITDA pushing above ~2×; or a cut/withdrawal of FY guidance signaling a cyclical rollover.
11. Key risks
Construction cyclicality (structural): the dominant risk — a US/European building downturn (rates, recession, budget cuts) hits volumes, pricing and the roll-up simultaneously. Q1 seasonal losses already show how operating leverage cuts both ways.
Roll-up / goodwill risk: growth leans on continuous M&A; goodwill+intangibles are 25% of assets. Overpaying or an integration stumble would impair returns (a small divestiture-related impairment already appeared in Q1'26).
Leverage creep: net-debt/EBITDA rose from ~1.0× to ~1.5× as buybacks/M&A outran FCF — manageable now, but a watch item in a downturn.
No momentum / lagging tape: below both moving averages and trailing SPY and QQQ — you're buying a laggard, so patience is required.
Policy/rate sensitivity: infrastructure demand depends on public budgets and IIJA continuity; higher-for-longer rates pressure private construction.
No expert corroboration: unlike our conviction names, zero KB coverage — this call has no independent analyst breadth behind it, so treat the confidence accordingly.
12. Verdict, position sizing & monitoring
Buy — Tactical. CRH is a well-run, cash-generative, North-America-levered building-materials leader trading at a cheap ~8× EV/EBITDA with 23% ROE, a real infrastructure tailwind, management reaffirming a solid FY26 guide, and ~+19% upside to our base-case fair value. It is not a conviction-track name — no expert in our KB covers it — and it is a cyclical whose price is currently lagging (below both moving averages, −18% off highs). So it earns a tactical/value Buy, not a Core rating.
Sizing:tactical/cyclical value, ~2–3% satellite weight. Because the tape is weak, scale in (starter now, adds on a reclaim of the 200-DMA ~$115 or on a demand-confirming Q2 print) rather than a single lump.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with special attention to organic volume, margin, and leverage. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $107.53.
Single biggest risk: construction cyclicality — a building downturn would hit volumes, pricing and the acquisition engine at once.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of CRH in the Synthos knowledge base, so no claim_ids are cited and none are fabricated. This is a fundamentals-/quant-driven note, and its lower conviction rating reflects that honestly.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K filed 2026-04-30. Forward figures are analyst consensus (FMP) or our own scenario model, labeled as estimates.
Management caveat: FY26 guidance ($3.9–4.1bn net income; $8.1–8.5bn Adjusted EBITDA) is management's own self-filed book, half-weighted by design.
Currency note: income statement and quote are in USD; FMP segment data is reported in EUR — segment splits are used as a mix guide, not a dollar reconciliation.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").